Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome

Table 1 Clinical characteristics of patients with nonalcoholic fatty liver disease and of those without nonalcoholic fatty liver disease

	Patients with NAFLD(n = 32)	Patients without NAFLD(n = 383)	P value
Age (yr)	77.4 ± 7.7	78.8 ± 6.4	NS
Males (%)	40	37.1	NS
Systolic blood pressure (mmHg)	150 ± 24	145 ± 24	NS
Diastolic blood pressure (mmHg)	84 ± 18	80 ± 13	NS
Hypertension	80%	82.5%	NS
Smoking (current/past)	17.4%/17.4%	10.9%/22.9%	NS
Package-years	17 ± 30	11 ± 31	NS
Type 2 diabetes mellitus	24%	31.8%	NS
Type 2 diabetes mellitus duration (yr)	3.9 ± 9.9	3.1 ± 6.7	NS
Atrial fibrillation	29.2%	38.9%	NS
Alcohol consumption (units/wk)	1.2 ± 2.5	2.3 ± 12.4	NS
Waist (cm)	107 ± 13	104 ± 12	NS
Waist/hip	1.03 ± 0.05	0.97 ± 0.07	NS
Body mass index (kg/m2)	26.9 ± 3.5	27.3 ± 5.0	NS
Overweight/obese	47.1 %/17.6 %	40.7 %/24.3 %	NS
Family history of cardiovascular disease	31.8%	14.7%	NS
Coronary heart disease	37.5%	27.6%	NS
Previous ischemic stroke	21.7%	43.5%	NS
Chronic kidney disease	31.6%	35.1%	NS
Chronic heart failure	23.8%	23.2%	NS

NS: Not significant; NAFLD: Nonalcoholic fatty liver disease.

Table 2 Laboratory characteristics of patients with nonalcoholic fatty liver disease and of those without nonalcoholic fatty liver disease

	Patients with NAFLD(n = 32)	Patients without NAFLD(n = 383)	P value
Glucose (mg/dL)	125 ± 64	113 ± 46	NS
LDL-C (mg/dL)	112 ± 42	112 ± 40	NS
HDL-C (mg/dL)	39 ± 12	47 ± 15	<0.05
Triglycerides (mg/dL)	144 ± 65	119 ± 51	<0.05
Uric acid (mg/dL)	5.6 ± 1.8	5.7 ± 1.8	NS
eGFR (mL/min/1.73 m2)	65 ± 19	69 ± 23	NS
Alanine aminotransferase (U/L)	35 ± 21	17 ± 13	<0.001
Aspartate aminotransferase (U/L)	56 ± 23	23 ± 17	<0.001
γ-glutamyl transpeptidase (U/L)	38 ± 29	24 ± 31	<0.05
Alkaline phosphatase (U/L)	71 ± 24	71 ± 32	NS
Total bilirubin (mg/dL)	0.83 ± 0.46	0.77 ± 0.48	NS
Direct bilirubin (mg/dL)	0.30 ± 0.19	0.28 ± 0.28	NS
Creatine kinase (U/L)	91 ± 40	119 ± 197	NS

LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; eGFR: Estimated glomerular filtration rate; NS: Not significant; NAFLD: Nonalcoholic fatty liver disease.

Table 3 Severity of stroke and outcome of patients of patients with nonalcoholic fatty liver disease and of those without nonalcoholic fatty liver disease

	Patients with NAFLD(n = 32)	Patients without NAFLD(n = 383)	P value
National Institutes of Health Stroke Scale score at admission	6.3 ± 6.4	8.8 ± 9.6	NS
Duration of hospitalization (d)	8.0 ± 5.1	6.7 ± 4.2	NS
Modified Rankin scale score at discharge	1.9 ± 2.2	2.6 ± 2.2	NS
Dependency at discharge	36.8%	55%	NS
Adverse outcome	42.9%	58.6%	NS
In-hospital mortality	8%	7%	NS

NS: Not significant; NAFLD: Nonalcoholic fatty liver disease.